Mirum Pharmaceuticals Inc (MIRM) - Total Assets
Based on the latest financial reports, Mirum Pharmaceuticals Inc (MIRM) holds total assets worth $890.92 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mirum Pharmaceuticals Inc - Total Assets Trend (2018–2025)
This chart illustrates how Mirum Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Mirum Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
Mirum Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Mirum Pharmaceuticals Inc's total assets of $890.92 Million consist of 65.2% current assets and 34.8% non-current assets. Review total liabilities of Mirum Pharmaceuticals Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.2% |
| Accounts Receivable | $123.33 Million | 14.6% |
| Inventory | $24.89 Million | 3.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $260.92 Million | 31.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Mirum Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Mirum Pharmaceuticals Inc share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mirum Pharmaceuticals Inc's current assets represent 65.2% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 35.2% of total assets in 2025, down from 100.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 31.0% of total assets.
Mirum Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Mirum Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Mirum Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.09 | 3.22 | 7.87 |
| Quick Ratio | 1.99 | 3.04 | 7.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $296.61 Million | $283.24 Million | $199.34 Million |
Mirum Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Mirum Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.50 |
| Latest Market Cap to Assets Ratio | 6.79 |
| Asset Growth Rate (YoY) | 25.7% |
| Total Assets | $842.81 Million |
| Market Capitalization | $5.73 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Mirum Pharmaceuticals Inc's assets at a significant premium (6.79x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Mirum Pharmaceuticals Inc's assets grew by 25.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mirum Pharmaceuticals Inc (2018–2025)
The table below shows the annual total assets of Mirum Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $842.81 Million | +25.65% |
| 2024-12-31 | $670.75 Million | +3.73% |
| 2023-12-31 | $646.62 Million | +83.23% |
| 2022-12-31 | $352.91 Million | +19.77% |
| 2021-12-31 | $294.65 Million | +22.33% |
| 2020-12-31 | $240.86 Million | +64.17% |
| 2019-12-31 | $146.71 Million | +182.27% |
| 2018-12-31 | $51.98 Million | -- |
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more